Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...
J&J revealed that its proposed prepackaged bankruptcy plan for Red River Talc LLC was not approved by the U.S. Bankruptcy Court for the Southern District of Texas. Instead of appealing, J&J plans to ...
Accessed March 2025. 3 J&J Data on file (RF-433976). European Medicines Agency. Updated TREMFYA Summary of Product Characteristics. Accessed March 2025. 5 EU SmPC: European Medicines Agency. TREMFYA ...
1don MSN
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...
In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...
Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback